The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created the legal pathway for biosimilar approval in the U.S., analogous to what Hatch-Waxman did for small-molecule generics [13]
Consultant haematologist Dr Priya Sriskandarajah published an article in Pulse Today including a link to a 2-hour CPD training course on key questions on vitamin B12 deficiency: CPD: Key questions on vitamin B12 deficiency
DG-75, BL-2, and Jurkat were cultured in RPMI 1640 medium (21875034), whereas HEK-293T were cultured in Dulbeccos modified Eagles medium (DMEM) (11965092), both from ThermoFisher Scientific (Waltham, MA, USA)
Tm li, glutathione khng nm trong danh sch cc cht bt buc b sung cho m bu, nhng cng khng hon ton b cm nu c s dng cn trng v c s gim st cht ch t bc s chuyn khoa
Alterations of the human gut microbiome in multiple sclerosis

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods
